Michael McDonald advises on all types of mergers and acquisitions, as well as joint ventures and restructurings.
He has represented corporates, financial institutions, and private equity funds on a broad range of public and private M&A transactions in various sectors, often involving cross-border issues. He has particular experience on European acquisitions by North American corporates and private equity funds.
Michael joined the firm in 2006 as a partner. Prior to Cleary he was an English-qualified M&A partner at Allen & Overy in London.
Agilent in its acquisition of Danish-based cancer diagnostics company Dako from EQT.
Amgen in its acquisition of Mustafa Nevzat Pharmaceuticals (MN), the Turkish biotech company.
Keysight Technologies in its takeover offer for Anite plc.
Stanley Black & Decker in its public takeover of Niscayah, and Truvo in its global restructuring.
UTC in its acquisition of Rentokil’s global security division.
3M Company in its public takeover of Biotrace International plc.
3M Company in its public takeover of E Wood Holdings plc.
QIA in relation to the acquisition by a consortium of National Grid’s gas distribution business in the UK.
Barclays on the sale of its global index business to Bloomberg.
TPG Capital in its acquisition of TSL Education Group Limited (TSL) from Charterhouse Capital Partners.
Dexia SA in the sale of its 50 percent stake in RBC Dexia Investor Services Limited to Royal Bank of Canada.
Highstar Capital on the sale of its 25 percent stake in London City Airport to a consortium.
JC Flowers in the sale of NIBC to Kaupthing as well as the acquisition of Fidea.